; and (4) not later than 12 months after the date of the enactment of this Act, submit to Congress a report that includes best practices identified and a proposed plan for disseminating and supporting adoption of such best practices by state prescription drug monitoring programs. (b) Input from relevant stakeholders In developing best practice guidelines under subsection (a), the Director of the Bureau of Justice Assistance and the Director of the Centers for Disease Control and Prevention, acting jointly, shall conduct a public workshop and otherwise engage with relevant stakeholders to help inform the development of best practices to— (1) identify patients at the highest risk for misuse of controlled substances and identify potential inappropriate prescribing trends; (2) identify potential data elements to include in proactive, unsolicited reports that are generated and disseminated to authorized users to identify such patients at the highest risk and identify potential inappropriate prescribing trends, and assess whether data on prescriptions for medication assisted treatments for substance use disorder and opioid overdose reversal agents should be incorporated and specific considerations for prescribers based on such information; and (3) identify additional enhancements to prescription drug monitoring programs and potential barriers to adoption and recommendations for addressing such barriers. (c) Grants (1) In general The Director of the Bureau of Justice Assistance and the Director of the Centers for Disease Control and Prevention, acting jointly, shall award grants to States to support adoption of best practices identified under subsection (b). (2) Amount of awards The total amount awarded to any State under this subsection shall be— (A) not less than $25,000